Mersana Therapeutics (NASDAQ:MRSN) will be posting its quarterly earnings results before the market opens on Tuesday, November 13th. Analysts expect Mersana Therapeutics to post earnings of ($0.59) per share for the quarter.
Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings data on Wednesday, August 15th. The company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.04. The firm had revenue of $4.19 million for the quarter, compared to analyst estimates of $3.74 million. Mersana Therapeutics had a negative return on equity of 72.63% and a negative net margin of 276.81%. On average, analysts expect Mersana Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of MRSN traded down $0.11 on Wednesday, reaching $6.60. The stock had a trading volume of 565 shares, compared to its average volume of 79,329. The stock has a market cap of $159.06 million, a PE ratio of -2.05 and a beta of 1.20. Mersana Therapeutics has a 12-month low of $5.82 and a 12-month high of $23.96.
In other Mersana Therapeutics news, insider Timothy B. Lowinger sold 3,500 shares of Mersana Therapeutics stock in a transaction on Monday, September 24th. The stock was sold at an average price of $11.63, for a total transaction of $40,705.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 39.70% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Mersana Therapeutics stock. Bank of New York Mellon Corp raised its stake in shares of Mersana Therapeutics Inc (NASDAQ:MRSN) by 27.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,615 shares of the company’s stock after buying an additional 6,804 shares during the quarter. Bank of New York Mellon Corp owned about 0.14% of Mersana Therapeutics worth $564,000 at the end of the most recent quarter. 82.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This piece was published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2018/11/07/mersana-therapeutics-mrsn-to-release-earnings-on-tuesday.html.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Read More: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.